Abstracts tagged "Clinical Osteoporosis"

Abstract Number: 1144 • ACR Convergence 2021
Underestimation of the Fracture Risk by the FRAX Formula in Chronic Glucocorticoid Users: A 10-year Longitudinal Validation Study
Chi Chiu Mok¹, Ling Yin Ho², Sau Mei TSE² and Kar Li Chan³, ¹Tuen Mun Hospital, Hong Kong, China, ²Tuen Mun Hospital, Hong Kong, Hong Kong, ³Tuen Mun Hospital, Hong Kong
Background/Purpose: To compare the actual fracture incidence over 10 years in a longitudinal cohort of patients using glucocorticoids (GCs) with the risk prediction from FRAX…
Abstract Number: 1147 • ACR Convergence 2021
Therapeutic Inertia and Low Patient Compliance: Major Contributors to Low Treatment Rates in Patients with Osteoporosis with Clinical Vertebral Compression Fractures
Shiva Malaty, Paramvir Sidhu, Rustan Sharer and Soo Yeon Kim, HonorHealth Internal Medicine Residency, Scottsdale, AZ
Background/Purpose: Treatment rates with pharmacologic therapy after osteoporotic vertebral fracture are very low in the United States. Underlying causes of these low treatment rates are…
Abstract Number: 1265 • ACR Convergence 2021
Paradoxical Effect of Vitamin D on Bone Mineral Density in SLE
Michelle Petri¹, Jessica Li² and Daniel Goldman¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD
Background/Purpose: Osteoporosis with fractures is consistently one of the top three items in the SLICC/ACR Damage Index in cohort studies internationally. As vitamin D insufficiency…
Abstract Number: 1304 • ACR Convergence 2021
Increased Risk of Vertebral Fracture Among Patients with Psoriatic Arthritis: A Systematic Review and Meta-analysis
Patompong Ungprasert¹, Nipith Charoenngam², Ben Ponvilawan³, Jerapas Thongpiya⁴ and Pitchaporn Yingchoncharoen³, ¹Cleveland Clinic, Cleveland Heights, OH, ²Mount Auburn Hospital, Boston, MA, ³Mahidol University, Bangkok, Thailand, ⁴Mahdiol University, Bangkok, Thailand
Background/Purpose: Increased risk of vertebral fracture (VF) has been documented in several autoimmune diseases as a result of excessive inflammatory burden and use of corticosteroids.…
Abstract Number: 0445 • ACR Convergence 2021
Safety and Efficacy of Denosumab vs Risedronate in Patients with Glucocorticoid-Induced Osteoporosis and Rheumatoid Arthritis
Jonathan Adachi¹, Arkadi Chines², Shuang Huang², Kenneth Saag³, Willem Lems⁴ and Piet Geusens⁵, ¹McMaster University/St. Joseph's Healthcare, Hamilton, ON, Canada, ²Amgen Inc., Thousand Oaks, CA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴VUmc, Amsterdam, Netherlands, ⁵Maastricht University, Genk, Belgium
Background/Purpose: Denosumab (DMAb) is approved for the treatment of glucocorticoid (GC)–induced osteoporosis (GiOP). In a phase 3, international, active-controlled, double-blind, double-dummy study, treatment with DMAb…
Abstract Number: 1136 • ACR Convergence 2021
Risk of Osteoporosis in Patients with Systemic Sclerosis: A Cross-Sectional Analysis of Two European Prospective Cohorts
Charles Midol¹, Edgar Wiebe², Elise Siegert², Dörte Huscher³, David Launay⁴, Eric Hachulla⁴, Vincent Sobanski¹ and Frank Buttgereit⁵, ¹Univ. Lille, Inserm, CHU Lille, Service de Médecine Interne, U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000 Lille, France, Lille, France, ²Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Germany, Berlin, Germany, ³Institute of Biometry and Clinical Epidemiology, and Berlin Institute of Health, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁴Univ. Lille, Inserm, CHU Lille, Service de Médecine Interne, U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000 Lille, France, Lille Cedex, France, ⁵Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Patients with systemic sclerosis (SSc) are at high risk for osteoporosis (OPO) and fragility fractures, although their exact prevalences are unknown. This might be…
Abstract Number: 1139 • ACR Convergence 2021
Fracture Liaison Service Outcomes at a Southern California County Hospital Highlights Need for Health System Improvements
Muntarin Karim¹, lorien ahn², Jordan Thompson¹, Christina Downey³, Lorena Salto⁴ and Karina Torralba⁵, ¹Loma Linda University, Redlands, CA, ²loma linda university medical center, Loma Linda, CA, ³Loma Linda University Medical Center, Redlands, CA, ⁴Loma Linda University Health, Loma Linda, CA, ⁵Division of Rheumatology, Department of Medicine, Loma Linda University Healthcare, Loma Linda, CA
Background/Purpose: Osteoporosis causes significant morbidity and mortality in the elderly. Despite the benefits of treatment, < 25% of elderly patients who fracture receive treatment. A…
Abstract Number: 0115 • ACR Convergence 2020
Improving Osteoporosis Screening in Men at a Resident-run Primary Care Clinic: A Quality Improvement Project
Khiem Vu¹, Chima Ohadugha¹, Kevin Dao¹, Rabih Nayfe² and Andrew Mangano¹, ¹Grand Strand Medical Center, Myrtle Beach, SC, ²Carolina Health Specialists - Rheumatology, Myrtle Beach, SC
Background/Purpose: There are known indications for osteoporosis screening in women. However, osteoporosis also occurs in men and fragility fractures are linked to increased morbidity and…
Abstract Number: 0119 • ACR Convergence 2020
Fracture Liaison Service at an Academic Center with an Open Health System: 30-month Outcomes
Donna Jose¹, Micah Yu², Karina Torralba³, Christina Downey⁴, Justin Dunn⁵ and Vinicius Cabido⁵, ¹Loma Linda University Medical Center, Ontario, CA, ²Loma Linda University Medical Center, Loma Linda, CA, ³Loma Linda University School of Medicine, Redlands, CA, ⁴Loma Linda University Medical Center, Redlands, CA, ⁵Loma Linda University Medical Center, Loma Linda
Background/Purpose: Osteoporosis causes significant morbidity, mortality and healthcare burden. There continues to be a care gap in osteoporosis recognition, treatment and prevention. Several healthcare systems…
Abstract Number: 0124 • ACR Convergence 2020
Appropriate Timing of Denosumab Dosing and Subsequent Therapy After Discontinuation: An Academic Medical Center Experience
Hugo Raposo¹, Daniel Lindstrom¹ and Jonathan Cheah², ¹University of Massachusetts Medical School, Worcester, MA, ²University of Massachusetts Medical School, Shrewsbury, MA
Background/Purpose: Denosumab, a monoclonal antibody that binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) is a popular choice for osteoporosis therapy. However,…
Abstract Number: 0125 • ACR Convergence 2020
A Resident-Led Interdisciplinary Quality Improvement Initiative to Increase Osteoporosis Screening in an Urban Clinic
Catherine Teskin¹ and Hiba Sayed², ¹Christiana Care, Wilmington, ²Christiana Care, wilmington, DE
Background/Purpose: Osteoporosis is a major cause of morbidity and mortality in the United States. The USPSTF recommends screening all women age 65 and older or…
Abstract Number: 0128 • ACR Convergence 2020
Short-Term Monitoring of Denosumab Effect in Breast Cancer Patients Receiving Aromatase Inhibitors Using Radiofrequency Echographic Multi-Spectrometry (REMS) Technology on Femoral Neck
Rosachiara Forcignanò¹, Fiorella Anna Lombardi², Mariangela Ciccarese³, Eugenio Quarta⁴, Antonella Grimaldi⁵, Laura Quarta⁵, Delia Ciardo², Ernesto Casciaro², Paola Pisani², Francesco Conversano², Maurizio Muratore⁵ and Sergio Casciaro², ¹O.U. of Oncology, “Sacro Cuore di Gesù” Hospital, Gallipoli, Lecce, Italy, Gallipoli, Italy, ²National Research Council, Institute of Clinical Physiology, Lecce, Italy, Lecce, Italy, ³O.U. of Oncology, “Vito Fazzi” Hospital, ASL-LE, Lecce, Italy, Lecce, Italy, ⁴O.U. of Rheumatology, "Galateo" Hospital, ASL-LE, San Cesario di Lecce, Lecce, Italy, San Cesario di Lecce, Italy, ⁵O.U. of Rheumatology, “Galateo” Hospital, San Cesario di Lecce ASL-LE, Lecce, Italy, San Cesario di Lecce, Italy
Background/Purpose: The aim of the study was to carry out a short-term monitoring of the effect of aromatase inhibitors (AI) and Denosumab on bone health…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].